Legend Biotech Corporation
LEGN
$34.18
-$0.52-1.50%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 31.65% | 46.43% | 9.94% | -16.11% | -27.71% |
| Total Depreciation and Amortization | 10.05% | 9.71% | 12.91% | 16.40% | 21.86% |
| Total Amortization of Deferred Charges | -10.88% | -14.91% | -29.46% | -22.29% | 12.60% |
| Total Other Non-Cash Items | -46.33% | -82.95% | 113.72% | 348.96% | 1,493.57% |
| Change in Net Operating Assets | 1,289.29% | 100.63% | -61.51% | -138.81% | -104.34% |
| Cash from Operations | 54.63% | 60.23% | 8.89% | -95.39% | -57.12% |
| Capital Expenditure | 27.90% | 0.56% | -68.58% | 4.03% | -24.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -200.00% | -- | 100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26.77% | -1,410.87% | -261.16% | 300.96% | -2,260.39% |
| Cash from Investing | -22.57% | -1,993.80% | -286.30% | 220.36% | -5,157.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 49.18% | 25.02% | -24.29% | -44.65% | -239.29% |
| Issuance of Common Stock | -98.78% | -99.40% | 109.33% | 108.96% | 12.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.12% | -99.69% | 110.00% | 109.40% | 12.45% |
| Foreign Exchange rate Adjustments | 187.40% | 120.44% | 155.25% | 127.17% | -42.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -434.49% | -220.92% | -15.85% | 406.40% | -68.23% |
